Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

B-cell Malignancies 1

Interventions

pembrolizumab 259Cyclophosphamide 243Specimen Handling 198fludarabine 174Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 121Carboplatin 99Radiotherapy 92Paclitaxel 88venetoclax 82Cisplatin 82Gemcitabine 79fludarabine phosphate 78Injections 69Ipilimumab 64Dexamethasone 62atezolizumab 59Cetuximab 58Bevacizumab 58Radiation 56Fluorouracil 56Azacitidine 56durvalumab 54Radiosurgery 53Temozolomide 47Rituximab 44Oxaliplatin 44Docetaxel 44Irinotecan 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × tirabrutinib × 1 year × Clear all
NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated
203 enrolled 43 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡